State Street Corporation has filed a Schedule 13G revealing its ownership of 8,827,707 shares, representing a 5.4% stake in Novavax Inc. This filing, dated November 10, 2026, indicates a significant investment in the company, which specializes in biological products.

Novavax Inc., classified under the SIC code 2836, focuses on developing and manufacturing vaccines and related biological products. The company is publicly traded on the Nasdaq under the ticker NVAX. Recent filings from Novavax include a 10-Q on November 5 and an 8-K on the same day, indicating ongoing activity and reporting.

The Schedule 13G filing states that State Street has shared voting power of 8,362,217 shares and shared dispositive power of 8,827,707 shares. This level of ownership suggests that State Street is a notable player among Novavax's institutional investors.

State Street's investment may affect various stakeholders, including other investors and competitors in the biological products sector. The filing shows that State Street is not looking to influence control over Novavax but is instead holding shares in the ordinary course of business.

The filing does not specify what actions may follow this report, leaving the future direction of State Street's investment in Novavax uncertain.

The Schedule 13G filing also indicates that State Street Corporation is classified as a holding company (HC) and has a principal business office located at One Congress Street, Suite 1, Boston, MA. This classification reflects State Street's role as an investment advisor and its involvement in managing assets for clients.

Additionally, the filing specifies that State Street Corporation has subsidiaries such as SSGA Funds Management, Inc. and State Street Global Advisors, which further emphasizes its substantial presence in the investment management sector. These subsidiaries are categorized as investment advisers (IA), indicating their role in managing investment portfolios for various clients.

Importantly, the filing confirms that State Street's shares were acquired and are held in the ordinary course of business, with no intention of influencing control over Novavax Inc. This aligns with State Street's investment strategy, which typically focuses on long-term value creation rather than short-term control tactics.

It is worth noting that the filing does not provide any information regarding the specific reasons behind State Street's investment in Novavax or any potential future actions that may arise from this ownership stake.